The firm will evaluate VS-7375 as both monotherapy and in combination with Eli Lilly's EGFR inhibitor Erbitux in the study.

The firm hopes to overcome common dose-limiting toxicities with its PSMA-targeted radiotherapy while boosting potency versus competitors.

In a Phase I study, previously treated pediatric SMA patients exhibited reductions in a marker of neurodegeneration after salanersen treatment.

UCLA-led investigators say additional research is needed into why guideline-recommended genetic testing remains low among ...

The funding will support the development of Revolution's RAS(ON) inhibitor daraxonrasib in exchange for tiered royalties on its sales.

In a Phase I/II clinical trial, TKI-pretreated NSCLC patients given zidesamtinib had an overall response rate of 44 percent.

In the NEULARK trial, patients with early-stage LRRK2-driven Parkinson's disease will receive Neuron23's NEU-411 or a placebo.

NEW YORK – The US Food and Drug Administration on Monday approved AstraZeneca and Daiichi Sankyo's TROP2-directed antibody drug conjugate Datroway (datopotamab deruxtecan or dato-DXd) for previously ...

The funding comes from the Foundation Fighting Blindness' venture philanthropy arm, the Retinal Degeneration Fund.

NEW YORK – Exelixis on Sunday said it will discuss with regulatory authorities positive top-line results from a pivotal, Phase III trial showing an overall survival benefit for patients with ...

The agency maintains that the beta-amyloid-targeting drugs show too limited benefit to justify their cost to the National Health Service.